LDN 214117

Key Product Details

Product Description

LDN 214117 is a potent and selective inhibitor of type I bone morphogenic protein (BMP) receptor ALK2 (IC₅₀ = 24 nM). Shows preference for ALK1 and ALK2 over ALK3 and 164-fold selectivity for BMP6 inhibition (IC₅₀ = 100 nM) over TGF-β1. Exhibits improved kinome selectivity over K 02288 (Cat.No. 4986) and low cytotoxicity.

Licensing Information

Sold for research purposes under exclusive agreement from The Brigham and Women's Hospital Inc. US patent 14/776,302

Product Specifications for LDN 214117

The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.

Solubility

Preparing Stock Solutions for LDN 214117

The following data is based on the product molecular weight 419.52.

Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which all affect the solvent volumes required to prepare stock solutions.

Select a batch to recalculate based on the batch molecular weight:

1 Recalculate

Concentration / Solvent Volume / Mass	1 mg	5 mg	10 mg
1 mM	2.38 mL	11.92 mL	23.84 mL
5 mM	0.48 mL	2.38 mL	4.77 mL
10 mM	0.24 mL	1.19 mL	2.38 mL
50 mM	0.05 mL	0.24 mL	0.48 mL

Calculators

Background References

References are publications that support the biological activity of the product.

• Mohedas Structure-activity relationship of 3,5-diaryl-2-aminopyridine ALK2 inhibitors reveals unaltered binding affinity for fibrodysplasia ossificans progressiva causing mutants. J Med Chem. 2014 PMID: 25101911

Product Documents for LDN 214117